Effect of interferon in therapy of skin and head and neck tumors

Padovan, I; Brodarec, I; Ikíc, D.; Knezević, M; Sooś, E

doi:10.1007/bf00410690

Cited by 22 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It appears that the intratumoral route of administration may have the greatest direct antitumor effect (21). On the other hand, it has been shown that HLIFN, given IM or IV, initiates a multi¬ tude of immunomodulatory effects that may add to the antitumor response (25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Clinical Results of Leukocyte Interferon-Induced Tumor Regression in Resistant Human Metastatic Cancer Resistant to Chemotherapy and/or Radiotherapy-Pulse Therapy Schedule

Medenica¹,

Slack²

1985

Cancer Drug Delivery

View full text Add to dashboard Cite

The efficacy of Human 6 IFN (HLIFN) given in a pulse fashion was determined in a phase II study. Ninety-one cancer patients were evaluated (9 myeloma, 12 breast, 14 prostate, 9 melanoma, 4 renal, 6 astrocytoma, 7 ovarian, 9 large bowel, 7 gastric, 14 head and neck). They all had advanced progressive cancer that was resistant to chemotherapy and/or radiotherapy. Patients were treated by intramuscular injection of 6 X 10(2) I.U./m2 for three consecutive days every four weeks. 84 patients were evaluable. Complete clinical response was obtained in 23 patients (4 myeloma, 2 breast, 5 prostate, 1 melanoma, 1 renal, 2 astrocytoma, 2 ovarian, 2 large bowel, 1 gastric, 3 head and neck). Partial responses were observed in 35 patients (3 myeloma, 7 breast, 6 prostate, 4 melanoma, 1 renal, 2 astrocytoma, 3 ovarian, 4 head and neck). Objective responses were related (P less than 0.01) to serum IFN level, with complete and partial responses (P less than 0.01) more commonly seen in those patients whose serum IFN levels at two hours were in the range of 1000 to 1650 I.U./ml. Side effects resulting from pulse IFN were acceptable for this group of patients and consisted of fever, transient chills, malaise and asthenia, and transient thrombocytopenia and leukocytopenia. The extent of fever was directly related (P less than 0.01) to response, and was most elevated in patients who achieved objective responses. IFN administered in a pulse fashion appears to be more effective than daily IFN and merits further evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Results of Leukocyte Interferon-Induced Tumor Regression in Resistant Human Metastatic Cancer Resistant to Chemotherapy and/or Radiotherapy-Pulse Therapy Schedule

Medenica¹,

Slack²

1985

Cancer Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Responses for other common solid tumors such as bronchogenic carcinoma (33,34) and colon cancer (35,36) have been negative. Preliminary trials with crude alpha interferon preparations from Yugoslavia suggested some activity for head and neck cancers (37,38); however, these results have not been confirmed in the United States.…”

Section: Solid Tumorsmentioning

confidence: 70%

Biological therapy of cancer

Foon

1986

Breast Cancer Res Tr

View full text Add to dashboard Cite

Interferons and monoclonal antibodies are among the most promising biological approaches to cancer treatment which have so far been investigated. Both natural and recombinant interferon-alpha preparations have shown activity in a number of trials in hematologic malignancies, even in previously treated patients; activity in solid tumors, however, has been limited. Unconjugated monoclonal antibodies have been safely administered in several small trials and have had therapeutic value on occasion. In spite of a number of remaining problems and questions, monoclonal antibodies and their conjugates seem likely to find a number of distinct roles in cancer treatment; elimination of micrometastases and purging of bone marrow for grafting may be among these roles.

show abstract

“…IFN-β in nasopharyngeal cancer is the only indication that was established successfully [21]. Local administrations of interferons to the tumor were only casually reported over the years [22].…”

Section: Biological Modifiers In the Treatment Of Head And Neck Cancermentioning

confidence: 99%